Beam reports breakthrough results from BEAM-101's early-stage trial for severe sickle cell disease. Read more here.

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease ...

By Robb M. Stewart Beam Therapeutics' investigational modified cell therapy for treating sickle-cell disease has been granted orphan-drug status by the Food and Drug Administration.

“Sickle cell disease is a devasting disorder that affects approximately 100,000 people in the U.S., leading to anemia, severe pain, stroke and even early death. Receiving orphan drug designation ...

Beam Therapeutics will present new BEAM-101 data for sickle cell disease at EHA2025, detailing safety and efficacy in 17 patients.

Pressure cells were used to measure vertical and lateral earth pressures. A Totalcomp TS-B10-10K-SS S-beam load cell was used in this study to measure the applied load. The DTs employed were strain ...

Beam Therapeutics has announced significant progress in its clinical trials and portfolio regarding precision genetic medicines, particularly in the area of sickle cell disease (SCD). Over 40 ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and efficacy results, and progresses on Aalpha-1 Antitrypsin Deficiency ...

Eight of these patients have been dosed with BEAM-101, while the other enrolled patients are going through pre-transplant stages, including cell collection and drug product manufacturing.

MIT researchers have developed a miniature, chip-based “tractor beam,” like the one that captures the Millennium Falcon in the film “Star Wars,” that could someday help biologists and clinicians study ...